CAS Number: 21462-39-5
Cleocin | 21462-39-5
Cleocin is the brand name for the antibiotic clindamycin, which is used to treat a variety of bacterial infections, including skin and soft tissue infections (such as cellulitis and acne), respiratory infections like pneumonia, dental infections, bone and joint infections, and certain abdominal or pelvic infections. It works by stopping bacteria from producing the proteins they need to grow, thereby helping the body eliminate the infection. Cleocin is available in several forms, including oral capsules or liquid, topical gels or solutions (often for acne), and injectable forms used in hospitals. Common side effects include nausea, vomiting, diarrhea, and abdominal pain. However, a serious risk associated with Cleocin is Clostridioides difficile–associated diarrhea (C. diff), which can cause severe, persistent diarrhea and stomach cramps, requiring prompt medical attention. Patients should take Cleocin exactly as prescribed, complete the full course, avoid skipping doses, and inform their doctor if they have a history of gut issues or colitis.
Product Information
HM Chemical Trading GmbH supplies industrial-grade specialty chemicals and raw materials with reliable international logistics support.
References
-
The Efficacy and Safety of a Single Dose of Clindesse™ Vaginal Cream for the Treatment of Bacterial Vaginosis
This multicenter, randomized, single-blind, parallel-group study compared the efficacy and safety of a single dose of Clindesse™ (clindamycin phosphate 2% in a sustained-release vaginal cream) with a 7-day regimen of Cleocin® (conventional clindamycin phosphate 2% vaginal cream) for treating bacterial vaginosis (BV). A total of 540 nonpregnant women with BV were enrolled. Efficacy was assessed 21–30 days after treatment initiation using multiple endpoints, including Investigator Cure, Clinical Cure (resolution of all four Amsel’s criteria plus Investigator Cure), Nugent Cure (Nugent score < 4), and Therapeutic Cure (combination of Clinical and Nugent Cure). Results showed no statistically significant differences between the two groups for any efficacy endpoint (all P > 0.05). The 95% confidence intervals for treatment differences supported equivalence. Adverse event rates were also similar between groups. The study concluded that a single dose of Clindesse™ is as safe and effective as a 7-day course of Cleocin® for treating BV, offering the advantage of improved convenience and potential compliance.
DOI: 10.1080/10647440500148321